Clinical Trial Update: A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant chemotherapy plus anlotinib for Stage III non-small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Stage III Non-small-cell Lung Cancer | Phase 2 | Status: UNKNOWN